Overview

Open-Label Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of EXPAREL® Administered Via a Single Intrathecal Injection to Healthy Volunteers

Status:
Not yet recruiting
Trial end date:
2022-12-16
Target enrollment:
Participant gender:
Summary
Primary Objective: To assess the safety and tolerability of EXPAREL administered as a single intrathecal injection in healthy volunteers. Secondary Objective: To characterize the pharmacokinetic (PK) and pharmacodynamic (PD) profile of EXPAREL administered as a single intrathecal injection in healthy volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
Pacira Pharmaceuticals, Inc